Skip to content
2000
Volume 20, Issue 4
  • ISSN: 2772-4344
  • E-ISSN: 2772-4352

Abstract

Background

The recent COVID-19 wave showed a significant rise in mucormycosis, changing its prevalence, particularly in India. Sadly, the total risk of mortality due to COVID-19 associated mucormycosis (CAM) remains high. It may be better to introduce a combination of drugs rather than unacceptable poor outcomes with Amphotericin B monotherapy.

Aim

The aim of this study is to assess the proportion of mucormycosis patient’s clinical outcomes with antifungal agent (Amphotericin B of any forms alone) or combination drug therapy (Amphotericin B of any form and Posaconazole).

Methods

It was a retrospective cohort study conducted between April 1st, 2021 and July 31st, 2021 at the tertiary care teaching hospital All India Institutes of Medical Sciences (AIIMS), Raipur.

Results

Out of 271 medical records of CAM patients, 211 records were included in the study. Among them, 46 patients (21.8%) received group 1 treatment . Amphotericin only and 165 patients (78.2%) received group 2 treatment, . Amphotericin B with Posaconazole. Group 2 was associated with a longer time to event, having a higher survival rate. The Hazard Ratio (HR) was 0.22 (95% CI – 0.13-0.36, -value 0.000).

Conclusion

Our findings will support the need for future studies to determine the efficacy of AMB and posaconazole combination therapy in the treatment of mucormycosis and to produce an evidence-based standard treatment regimen.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/raaidd/10.2174/0127724344355666250513101536
2025-11-01
2025-12-06

  • From This Site

    /content/journals/raaidd/10.2174/0127724344355666250513101536
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Kwon-ChungK.J. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: Molecular mycologic perspectives.Clin. Infect. Dis.2012541S8S1510.1093/cid/cir864 22247451
     [Google Scholar]
  2. JeongW. KeighleyC. WolfeR. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports.Clin. Microbiol. Infect.2019251263410.1016/j.cmi.2018.07.011 30036666
     [Google Scholar]
  3. IbrahimAS SpellbergB WalshTJ KontoyiannisDP Pathogenesis of mucormycosis.Clin Infect Dis201254Suppl 1)(Suppl. 1S162210.1093/cid/cir86522247441
     [Google Scholar]
  4. VaughanC. BartoloA. VallabhN. LeongS.C. A meta‐analysis of survival factors in rhino‐orbital‐cerebral mucormycosis—has anything changed in the past 20 years?Clin. Otolaryngol.20184361454146410.1111/coa.13175 29947167
     [Google Scholar]
  5. BanerjeeM. PalR. BhadadaS.K. Intercepting the deadly trinity of mucormycosis, diabetes and COVID-19 in India.Postgrad. Med. J.202298e2e108e10910.1136/postgradmedj‑2021‑140537 37066526
     [Google Scholar]
  6. JohnT.M. JacobC.N. KontoyiannisD.P. When uncontrolled diabetes mellitus and severe COVID-19 converge: The perfect storm for mucormycosis.J. Fungi (Basel)20217429810.3390/jof7040298 33920755
     [Google Scholar]
  7. NithyanandamS. JacobM.S. BattuR.R. ThomasR.K. CorreaM.A. D’SouzaO. Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes.Indian J. Ophthalmol.2003513231236 14601848
     [Google Scholar]
  8. SharifiA. AkbariZ. Shafie’eiM. Retrobulbar injection of amphotericin b in patients with COVID-19 associated orbital mucormycosis: A systematic review.Ophthal. Plast. Reconstr. Surg.202238542543210.1097/IOP.0000000000002256 35943425
     [Google Scholar]
  9. SardaR. SwainS. RayA. WigN. COVID-19-associated mucormycosis: An epidemic within a pandemic.QJM2021114635535610.1093/qjmed/hcab165 34109406
     [Google Scholar]
  10. PrakashH. ChakrabartiA. Global epidemiology of mucormycosis.J. Fungi (Basel)2019512610.3390/jof5010026 30901907
     [Google Scholar]
  11. FortunJ. GioiaF. CardozoC. Posaconazole salvage therapy: The Posifi study.Mycoses201962652653310.1111/myc.12911 30864238
     [Google Scholar]
  12. RosarioD.K.A. MutzY.S. BernardesP.C. Conte-JuniorC.A. Relationship between COVID-19 and weather: Case study in a tropical country.Int. J. Hyg. Environ. Heal202022911358710.1016/j.ijheh.2020.113587 32917371
     [Google Scholar]
  13. SpellbergB. WalshT.J. KontoyiannisD.P. EdwardsJ.Jr IbrahimA.S. Recent advances in the management of mucormycosis: From bench to bedside.Clin. Infect. Dis.200948121743175110.1086/599105 19435437
     [Google Scholar]
  14. AL-KhikaniF.O. Amphotericin B as antiviral drug: Possible efficacy against COVID-19.Ann. Thorac. Med.202015311812410.4103/atm.ATM_147_20 32831932
     [Google Scholar]
  15. GargD. MuthuV. SehgalI.S. Coronavirus disease (COVID-19) associated mucormycosis (CAM): Case report and systematic review of literature.Mycopathologia2021186228929810.1007/s11046‑021‑00528‑2 33544266
     [Google Scholar]
  16. KayaratB. KhannaP. Posaconazole in the prevention of COVID-19-associated mucormycosis: A concerning contributor to the rise in antifungal resistance.Indian J. Crit. Care Med.2021251012091210 34916761
     [Google Scholar]
  17. RodríguezM.M. SerenaC. MarinéM. PastorF.J. GuarroJ. Posaconazole combined with amphotericin B. An effective therapy for a murine disseminated infection caused by Rhizopus oryzae.Antimicrob. Agents Chemother.200852103786378810.1128/AAC.00628‑08 18694953
     [Google Scholar]
  18. LuoG. GebremariamT. LeeH. Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis.Antimicrob. Agents Chemother.20135773340334710.1128/AAC.00313‑13 23650163
     [Google Scholar]
  19. DravidA. KashivaR. KhanZ. Epidemiology, clinical presentation and management of COVID‐19 associated mucormycosis: A single centre experience from Pune, Western India.Mycoses202265552654010.1111/myc.13435 35212032
     [Google Scholar]
  20. ReedC. BryantR. IbrahimA.S. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis.Clin. Infect. Dis.200847336437110.1086/589857 18558882
     [Google Scholar]
  21. HindujaA.R.A. TambeR.R. GiriP.A. SunilS. LimayeH. KalpanaG. Mucormycosis and diabetes in the times of COVID-19: A Mumbai-based observational study.J. Family Med. Prim. Care202211106107611410.4103/jfmpc.jfmpc_291_22 36618183
     [Google Scholar]
  22. CornelyO.A. MaertensJ. BresnikM. Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).Clin. Infect. Dis.200744101289129710.1086/514341 17443465
     [Google Scholar]
  23. ThangarajuP. TanguturiY.S.S. ArumugamR.V. Is daclatasvir a suitable substitute for amphotericin b in the treatment of mucormycosis when amphotericin B is scarce?Curr. Drug Res. Rev.202316151010.2174/2589977515666230430004013 37125653
     [Google Scholar]
  24. SamandarF. AmiriT.Z. SaberiM.R. ChamaniJ. 1,2,3,4,6-Pentagalloyl glucose of Pistacia lentiscus can inhibit the replication and transcription processes and viral pathogenesis of SARS-COV-2.Mol. Cell. Probes20226510184710.1016/j.mcp.2022.101847 35843391
     [Google Scholar]
  25. NoorH. IkramA. RathinavelT. KumarasamyS. NasirI.M. BashirZ. Immunomodulatory and anti-cytokine therapeutic potential of curcumin and its derivatives for treating COVID-19 – a computational modeling.J. Biomol. Struct. Dyn.202240135769578410.1080/07391102.2021.1873190 33491580
     [Google Scholar]
  26. Clinical trial registry of India (CLTRI).Available from: https://ctri.nic.in/Clinicaltrials/advsearch2.php (Accessed on: 20, Sep 2023).2023
  27. DhakalA. PokharelM. MadhupS. KhadkaL. SapkotaB. Rhino-orbital mucormycosis in a COVID-19 patient: A dreadful challenge.Kathmandu Univ. Med. J.202220224925110.3126/kumj.v20i2.51465 37017177
     [Google Scholar]
  28. Salmanton-GarcíaJ. SeidelD. KoehlerP. Matched-paired analysis of patients treated for invasive mucormycosis: Standard treatment versus posaconazole new formulations (MoveOn).J. Antimicrob. Chemother.201974113315332710.1093/jac/dkz344 31393591
     [Google Scholar]
  29. ManeshA. DevasagayamE. BhanuprasadK. Short intravenous amphotericin B followed by oral posaconazole using a simple, stratified treatment approach for diabetes or COVID-19-associated rhino-orbito-cerebral mucormycosis: A prospective cohort study.Clin. Microbiol. Infect.202329101298130510.1016/j.cmi.2023.06.017 37348653
     [Google Scholar]
  30. CacciapuotiA. GurnaniM. HalpernJ. NorrisC. PatelR. LoebenbergD. Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo.Antimicrob. Agents Chemother.200549263864210.1128/AAC.49.2.638‑642.2005 15673745
     [Google Scholar]
/content/journals/raaidd/10.2174/0127724344355666250513101536
Loading
Use of Any Form of Amphotericin B Alone or with Posaconazole in COVID-19 Associated Mucormycosis (CAM) at the Time of Pandemic Disaster in a Tertiary Care Teaching Hospital
Recent Adv Antiinfect Drug Discov 20, 326 (2025); https://doi.org/10.2174/0127724344355666250513101536
/content/journals/raaidd/10.2174/0127724344355666250513101536
/content/journals/raaidd/10.2174/0127724344355666250513101536
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Amphotericin B; antifungal; black fungus; COVID-19-associated mucormycosis; posaconazole; SARS-CoV-2

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test